FFA
VKTX icon

Fairfield Financial Advisors’s Viking Therapeutics VKTX Stock Holding History

Fairfield Financial Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-32
Closed -$1.29K – 195
2024
Q4 		$1.29K Hold
32
– – ﹤0.01% 246
2024
Q3 		$2.03K Hold
32
– – ﹤0.01% 267
2024
Q2 		$1.7K Buy
+32
New +$2.1K ﹤0.01% 264

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Fairfield Financial Advisors's VKTX Position: Q1 2025 in Review

Fairfield Financial Advisors sold out of Viking Therapeutics (VKTX) in Q1 2025, closing a stake of 32 shares — an estimated $1.29K sold.

Fairfield Financial Advisors first reported a position in VKTX in Q2 2024 and held it in 3 quarters. The position peaked at $2.03K in Q3 2024. 373 funds tracked by Wall St. Rank hold VKTX as of Q1 2025.

  • Fairfield Financial Advisors reported no remaining Viking Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Fairfield Financial Advisors sold 32 Viking Therapeutics shares in Q1 2025, an estimated $1.29K.
  • Fairfield Financial Advisors first reported a position in Viking Therapeutics in Q2 2024 and held it in 3 quarters.
  • Fairfield Financial Advisors's Viking Therapeutics position peaked at $2.03K in Q3 2024.
  • 373 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2025.

Based on Fairfield Financial Advisors's 13F filing for Q1 2025, filed 9 May 2025.